Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit
December 18, 2025
Congrats to Peel’s CEO for his talk at Colorectal Cancer Alliance‘s 2025 CureCRC Summit. PEEL-224 offers a new approach to treating cancer with better efficacy and less toxicity. Our company looks forward to continuing to test PEEL-224 in patients on multiple clinical trials.
PEEL-224 offers a new way of treating aggressive cancers like metastatic CRC. PEEL-224 is a new cancer medicine with a delivery optimized, novel TOPO1 inhibitor payload showing early promise for patients. Excited to introduce a new way to treat cancer with better efficacy and less toxicity.
Recent News
- Nucleus Institute Convergence Point Groundbreaking
- EDWARDS LIFESCIENCES RECEIVES FDA APPROVAL FOR AUTUS VALVE
- Route 92 Medical Announces U.S. FDA Clearance for the FreeClimb® 46 Catheter with Tenzing® 4
- Owlet Announces Creation of Baby Safety Task Force to Educate, Innovate, and Advocate for Better Baby Safety Standards
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Freyya Closes Oversubscribed Pre-Seed Financing to Advance FDA Regulatory Milestones, Commercialization
